High-Dose Aflibercept for AMD
How High-Dose Aflibercept Differs From Standard Treatment
High-dose aflibercept delivers 8 mg of aflibercept per injection, four times the concentration of the standard 2 mg formulation. According to Regeneron (2023), the FDA approved this formulation on August 18, 2023, for wet AMD, diabetic macular edema (DME), and diabetic retinopathy, making it the first 8 mg intravitreal anti-VEGF. The higher concentration is delivered in the same small injection volume as the standard dose, so the injection procedure feels the same for patients.
The key advantage is longer duration of action inside your eye. By delivering four times the standard concentration of medication to the back of your eye, high-dose aflibercept maintains effective VEGF suppression for a longer period between doses, allowing wider intervals between injections and fewer total office visits per year.
Like standard aflibercept, the high-dose formulation acts as a decoy receptor that traps VEGF-A and placental growth factor, preventing these proteins from triggering abnormal blood vessel growth and leaking in your retina. The higher concentration creates a larger reservoir of medication inside your eye, which takes longer to clear. This extended therapeutic presence means the abnormal blood vessels beneath your retina stay suppressed for more weeks between injections, reducing the chance of fluid recurrence during longer dosing intervals.
The PULSAR phase 3 trial enrolled 1,009 wet AMD patients and demonstrated that high-dose aflibercept at both 12-week and 16-week dosing intervals was non-inferior to standard aflibercept given every 8 weeks, after only three initial monthly loading doses (PubMed, 2024). At 96 weeks, 71 percent of patients achieved 16-week intervals or longer, and 47 percent reached 20-week intervals or more, according to Regeneron (2024). Three-year data showed continued durable vision gains with a safety profile consistent with standard aflibercept.
According to Regeneron (2026), the FDA approved expanded dosing intervals for high-dose aflibercept in April 2026, extending the approved range up to every 30 weeks for wet AMD and DME. This is the widest approved dosing range of any injectable anti-VEGF medication. Some patients may need only two to three injections per year once they reach extended intervals, a substantial reduction from the monthly or bimonthly schedules required by older treatments.
What Treatment Looks Like
Your retina specialist delivers high-dose aflibercept through the same intravitreal injection procedure used for all anti-VEGF medications. Numbing drops and antiseptic are applied to your eye. A small needle passes through the white part of your eye to deliver the medication into the vitreous cavity. The injection takes seconds and most patients feel pressure but not sharp pain. The injection volume is the same as standard aflibercept, so the procedure itself is identical.
According to FDA labeling (2023), treatment starts with 8 mg injections every four weeks for three months (the loading phase). After the loading phase, your retina specialist individualizes your interval, starting at every 8 to 16 weeks and potentially extending further based on your OCT imaging and visual acuity. Your doctor extends the interval step by step, checking OCT imaging for fluid return at each visit before approving a longer gap between injections. The individualized approach ensures your specific disease activity guides the pace of extension.
At each visit, your retina specialist performs OCT imaging to check for subretinal or intraretinal fluid. A dry retina means your current interval is working and may be extended further. Fluid on OCT prompts your doctor to shorten the interval to regain disease control. This treat-and-extend approach maximizes the time between injections while ensuring your retina stays protected from ongoing damage.
Safety and Side Effects
According to three-year PULSAR data (Regeneron, 2024-2025), the safety profile of high-dose aflibercept is consistent with standard aflibercept. No cases of occlusive retinal vasculitis or endophthalmitis occurred in the high-dose groups through two years. Common side effects include temporary blurred vision, conjunctival hemorrhage (bleeding on the white of the eye), mild eye discomfort, and floaters. These resolve within days.
The same rare injection-related risks that apply to all intravitreal injections apply here: endophthalmitis, retinal detachment, and traumatic cataract, all occurring in fewer than 0.1 percent of injections. The risk does not increase with higher medication concentration since the injection volume and procedure are identical to standard dosing. Your retina specialist uses sterile technique and careful needle placement to minimize these risks.
Contact your retina specialist the same day if you develop increasing eye pain, sudden vision loss, a significant increase in floaters or flashes, or worsening redness after an injection. These symptoms may indicate a rare complication that requires urgent treatment to preserve your vision. Do not wait for your next scheduled appointment.
Questions About High-Dose Aflibercept
High-dose aflibercept provides the same class of visual benefit as the standard formulation. The primary advantage is longer time between injections, not superior vision gain. Patients who achieve extended intervals reduce their annual visit burden without sacrificing disease control. Your retina specialist recommends the formulation that best fits your treatment needs.
Your retina specialist can transition you from standard aflibercept or another anti-VEGF medication to the high-dose formulation. This switch is common for patients who want to reduce their injection frequency or who have stable disease on the standard dose and could benefit from wider intervals. Your doctor monitors your response closely after the transition.
After the three-month loading phase, the number of injections depends on how far your doctor can extend your interval. Patients on 16-week intervals need about three additional injections per year. Those reaching 20- to 30-week intervals may need only two to three per year. Your doctor sets the pace based on your OCT results at each visit.
Medicare Part B covers physician-administered anti-VEGF injections for wet AMD. Most commercial insurance plans also cover high-dose aflibercept, though prior authorization may be required. Your retina specialist can verify coverage before starting treatment. Cost-minimization studies suggest high-dose aflibercept may achieve the lowest total per-patient treatment cost over three years due to fewer required injections.
No. The 8 mg dose is a higher concentration delivered in the same small injection volume. The needle, the procedure, and the post-injection experience are identical to the standard dose. You will not feel a difference during the injection itself.
If OCT imaging shows fluid return at your current interval, your retina specialist shortens the time between injections to bring the disease back under control. Once the retina dries again, your doctor may attempt to re-extend the interval more cautiously. Fluid recurrence does not mean the medication has stopped working; it means your current interval is slightly too long for your disease activity.
Ask About Extended-Interval Treatment
If you are receiving anti-VEGF injections for wet AMD, ask your retina specialist whether high-dose aflibercept could reduce the number of injections and visits you need each year while maintaining your visual results.